Abstract
Very little data are available on the usefulness of oxcarbazepine in young children with epilepsy. From January 1991 through October 1994, we treated 53 children under age 7 years with oxcarbazepine. The mean follow-up with oxcarbazepine treatment was 13 months. Etiology was symptomatic in 39, cryptogenic in 12, and idiopathic in 2 children. Forty-three children had previously been intractable to one or more antiepileptic drugs (including carbamazepine in 30 patients) and two had carbamazepine hypersensitivity. The age at onset of oxcarbazepine therapy ranged from 0.6 to 6.9 years (mean, 3.9 yr). The mean maximum oxcarbazepine dose was 50 mg/kg/day (range, 21-86 mg/kg/day). Of the children with localization-related epilepsy, 12 of 44 (27%) became seizure free and an additional 16 of 44 (36%) had an at least 50% reduction of seizures. Five of nine children with generalized epilepsy also had some benefit but none became seizure free. In the 33 children with at least 50% seizure reduction, the mean effective dose and trough serum level of the active metabolite monohydroxycarbazepine were 47 mg/kg/day (range, 21-75 mg/kg/day) and 91 micromol/L (range, 42-130 micromol/L), respectively. Efficacy was transient in 4 children; side effe...Continue Reading
References
Aug 1, 1992·Acta Neurologica Scandinavica·T KeränenP Andersson
Jan 1, 1991·Epilepsia·R R Clancy, A Legido
Jan 1, 1989·Epilepsy Research·M DamK Jakobsen
Nov 1, 1987·Epilepsia·M A HoutkooperJ A Hulsman
Sep 1, 1987·Epilepsy Research·K J ReinikainenP J Riekkinen
Sep 1, 1994·Epilepsy Research·J A Van Parys, H Meinardi
Jan 1, 1994·Epilepsia·A BaruzziR Riva
Mar 1, 1993·Acta Neurologica Scandinavica·M L FriisJ Worm-Petersen
Citations
Dec 7, 2000·Mental Retardation and Developmental Disabilities Research Reviews·J M Pellock, L D Morton
May 19, 2001·Neurologic Clinics·K D Holland
Mar 27, 2003·Pediatric Neurology·Gul SerdarogluBerrak Sarioglu
Jul 15, 2000·Clinical Neuropharmacology·B F Bourgeois
Oct 26, 1999·Epilepsia·E S Tecoma
Jul 25, 2007·Epilepsia·Martina VendrameSanjeev V Kothare
Jan 1, 2000·International Journal of Adolescent Medicine and Health·James J Riviello
Jul 2, 2008·Paediatric Drugs·Allison M Chung, Lea S Eiland
Oct 2, 2013·Paediatric Drugs·Shu-Hao WeiPi-Chuan Fan
Aug 16, 2001·Brain & Development·S J Wallace
Jun 8, 2001·Clinical Therapeutics·M M Kalis, N A Huff
Jul 5, 2005·Expert Opinion on Investigational Drugs·S C Schachter
Mar 16, 2001·Expert Opinion on Pharmacotherapy·P H McCabe
Oct 22, 2004·Journal of Clinical Pharmacology·Elisabeth ReyOlivier Dulac
Sep 26, 2006·Pediatric Neurology·Sanjeev V KothareAgustin Legido
Aug 31, 2006·Pediatric Neurology·Sanjeev V KothareAgustin Legido
Oct 26, 2005·Pediatric Neurology·Ralph S NorthamYvonne Sturm
Jun 14, 2000·Seizure : the Journal of the British Epilepsy Association·S Shorvon
Oct 16, 2016·Expert Opinion on Drug Safety·Xi Lu, Xuefeng Wang
Nov 6, 2004·Journal of Child Neurology·James W Wheless, Blaise F D Bourgeois
Mar 29, 2002·Journal of Child Neurology·James W Wheless
Feb 22, 2018·World Journal of Pediatrics : WJP·Jiong QinXiang-Shu Hu
Jun 25, 2017·World Journal of Pediatrics : WJP·Yi WangJiong Qin
Jul 6, 2000·Neurology·T A GlauserJ D'Souza